# APHEXDA® (motixafortide) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/motixafortide

> The FDA approved APHEXDA® (motixafortide), sponsored by BioLineRx Ltd. (BLRX), on September 8, 2023 for multiple myeloma.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | APHEXDA® (motixafortide) |
| Codes | BL-8040 |
| Sponsor | BioLineRx Ltd. (BLRX) https://sec-api.dev/companies/blrx/catalysts |
| Indications | [multiple myeloma](https://sec-api.dev/indications/multiple-myeloma), recurrent and progressive glioblastoma, [glioblastoma](https://sec-api.dev/indications/glioblastoma), stem-cell mobilization and solid tumors |
| Modality | peptide |
| FDA designations | orphan |

## Timeline

### May 2021: topline data readout

- Status: completed, met. Date confidence: month.
- First seen 2024-11-25, last confirmed 2024-11-25.
- Press release filed with the SEC (EX-99) (accession 0001178913-24-003823): "Top-line results announced in May 2021 showed highly statistically significant evidence across all primary and secondary endpoints favoring motixafortide in combination with G-CSF (p<0.0001)." https://www.sec.gov/Archives/edgar/data/1498403/000117891324003823/exhibit_3.htm

### Sep 2022: FDA approval

- Status: completed, approved. Date confidence: month. Indication: multiple myeloma.
- First seen 2025-03-31, last confirmed 2025-03-31.
- SEC Form 10-K (accession 0001178913-25-001123): "In September 2022, we submitted an NDA to the FDA for motixafortide in stem cell mobilization for autologous bone marrow transplantation for multiple myeloma patients and as noted above in September 2023, the FDA approved motixafortide in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma." https://www.sec.gov/Archives/edgar/data/1498403/000117891325001123/zk2532907.htm

### Sep 2022: NDA/BLA submission

- Status: completed. Date confidence: month. Indication: multiple myeloma.
- First seen 2025-03-31, last confirmed 2025-03-31.
- SEC Form 10-K (accession 0001178913-25-001123): "In September 2022, we submitted an NDA to the FDA for motixafortide in stem cell mobilization for autologous bone marrow transplantation for multiple myeloma patients and as noted above in September 2023, the FDA approved motixafortide in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma." https://www.sec.gov/Archives/edgar/data/1498403/000117891325001123/zk2532907.htm

### Sep 2023: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2025-08-14, last confirmed 2026-08-31.
- Press release filed with the SEC (EX-99) (accession 0001178913-26-004331): "Reported preliminary data in September 2023 from single-arm pilot phase of the investigator-initiated Phase 2 combination trial in first-line PDAC." https://www.sec.gov/Archives/edgar/data/1498403/000117891326004331/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-26-002934): "Reported preliminary data in September 2023 from single-arm pilot phase of the investigator-initiated Phase 2 combination trial in first-line PDAC." https://www.sec.gov/Archives/edgar/data/1498403/000117891326002934/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-003941): "Reported preliminary data in September 2023 from single-arm pilot phase of the investigator-initiated Phase 2 combination trial in first-line PDAC." https://www.sec.gov/Archives/edgar/data/1498403/000117891325003941/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-002883): "Reported preliminary data in September 2023 from single-arm pilot phase of the investigator-initiated Phase 2 combination trial in first-line PDAC." https://www.sec.gov/Archives/edgar/data/1498403/000117891325002883/exhibit_3.htm

### September 8, 2023: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: multiple myeloma.
- First seen 2024-11-25, last confirmed 2026-08-31.
- Press release filed with the SEC (EX-99) (accession 0001178913-26-004331): "In September 2023, the U.S. Food and Drug Administration ("FDA") approved motixafortide in stem cell mobilization for autologous transplantation for multiple myeloma patients, and the Company began to independently commercialize motixafortide in the U.S." https://www.sec.gov/Archives/edgar/data/1498403/000117891326004331/exhibit_2.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-26-004331): "In September 2023, the FDA approved motixafortide in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma." https://www.sec.gov/Archives/edgar/data/1498403/000117891326004331/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-26-002934): "In September 2023, the U.S. Food and Drug Administration ("FDA") approved motixafortide in stem cell mobilization for autologous transplantation for multiple myeloma patients, and the Company began to independently commercialize motixafortide in the U.S." https://www.sec.gov/Archives/edgar/data/1498403/000117891326002934/exhibit_2.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-26-002934): "In September 2023, the FDA approved motixafortide in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma." https://www.sec.gov/Archives/edgar/data/1498403/000117891326002934/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-003941): "In September 2023, the U.S. Food and Drug Administration ("FDA") approved motixafortide in stem cell mobilization for autologous transplantation for multiple myeloma patients, and the" https://www.sec.gov/Archives/edgar/data/1498403/000117891325003941/exhibit_2.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-003941): "In September 2023, the FDA approved motixafortide in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma." https://www.sec.gov/Archives/edgar/data/1498403/000117891325003941/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-002883): "In September 2023, the U.S. Food and Drug Administration ("FDA") approved motixafortide in stem cell mobilization for autologous transplantation for multiple myeloma patients, and the Company began to independently commercialize motixafortide in the U.S." https://www.sec.gov/Archives/edgar/data/1498403/000117891325002883/exhibit_2.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-002883): "In September 2023, the FDA approved motixafortide in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma." https://www.sec.gov/Archives/edgar/data/1498403/000117891325002883/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-001952): "In September 2023, the U.S. Food and Drug Administration ("FDA") approved motixafortide in stem cell mobilization for autologous transplantation for multiple myeloma patients, and the Company began to independently commercialize motixafortide in the U.S." https://www.sec.gov/Archives/edgar/data/1498403/000117891325001952/exhibit_2.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-001952): "In September 2023, the FDA approved motixafortide in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma." https://www.sec.gov/Archives/edgar/data/1498403/000117891325001952/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-24-003823): "In September 2023, the U.S. Food and Drug Administration ("FDA") approved motixafortide in stem cell mobilization for autologous transplantation for multiple myeloma patients, and the Company began to independently commercialize motixafortide in the U.S." https://www.sec.gov/Archives/edgar/data/1498403/000117891324003823/exhibit_2.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-24-003823): "In September 2023, the FDA approved motixafortide in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma." https://www.sec.gov/Archives/edgar/data/1498403/000117891324003823/exhibit_3.htm

### Nov 2023: trial start

- Status: completed. Date confidence: month.
- First seen 2024-11-25, last confirmed 2026-08-31.
- Press release filed with the SEC (EX-99) (accession 0001178913-26-004331): "In November 2023, we initiated pivotal bridging study preparation activities with Gloria, our Asia partner, to support potential approval and commercialization of motixafortide in stem-cell mobilization in China." https://www.sec.gov/Archives/edgar/data/1498403/000117891326004331/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-26-002934): "In November 2023, we initiated pivotal bridging study preparation activities with Gloria, our Asia partner, to support potential approval and commercialization of motixafortide in stem-cell mobilization in China." https://www.sec.gov/Archives/edgar/data/1498403/000117891326002934/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-003941): "In November 2023, we initiated pivotal bridging study preparation activities with Gloria, our Asia partner, to support potential approval and commercialization of motixafortide in stem-cell mobilization in China." https://www.sec.gov/Archives/edgar/data/1498403/000117891325003941/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-002883): "In November 2023, we initiated pivotal bridging study preparation activities with Gloria, our Asia partner, to support potential approval and commercialization of motixafortide in stem-cell mobilization in China." https://www.sec.gov/Archives/edgar/data/1498403/000117891325002883/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-001952): "In November 2023, we initiated pivotal bridging study preparation activities with Gloria, our Asia partner, to support potential approval and commercialization of motixafortide in stem-cell mobilization in China." https://www.sec.gov/Archives/edgar/data/1498403/000117891325001952/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-24-003823): "In November 2023, we initiated pivotal bridging study preparation activities with Gloria, our Asia partner, to support potential approval and commercialization of motixafortide in stem-cell mobilization in China." https://www.sec.gov/Archives/edgar/data/1498403/000117891324003823/exhibit_3.htm
- SEC Form 10-K (accession 0001178913-26-001581): "In November 2023, we initiated pivotal bridging study preparation activities with Gloria, our Asia partner, to support potential approval and commercialization of motixafortide in stem-cell mobilization in China." https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/zk2634707.htm
- SEC Form 10-K (accession 0001178913-25-001123): "In November 2023, we initiated pivotal bridging study preparation activities with Gloria, our Asia partner, to support potential approval and commercialization of motixafortide in stem-cell mobilization in China." https://www.sec.gov/Archives/edgar/data/1498403/000117891325001123/zk2532907.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-002883): "First patient dosed in December 2023 and initial data from the study released in November 2024." https://www.sec.gov/Archives/edgar/data/1498403/000117891325002883/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-001952): "As anticipated, the study began enrolling in 2023, with first patient dosed in December 2023, and is ongoing." https://www.sec.gov/Archives/edgar/data/1498403/000117891325001952/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-001952): "First patient dosed in December 2023 and initial data from the study released in November 2024." https://www.sec.gov/Archives/edgar/data/1498403/000117891325001952/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-24-003823): "The study began enrolling in 2023, with first patient dosed in December 2023, and is ongoing (timelines, as well as other study related decisions, are ultimately controlled by the independent investigator-sponsor and are, therefore, subject to change)." https://www.sec.gov/Archives/edgar/data/1498403/000117891324003823/exhibit_3.htm

### Feb 2024: trial start

- Status: completed. Date confidence: month.
- First seen 2024-11-25, last confirmed 2026-08-31.
- Press release filed with the SEC (EX-99) (accession 0001178913-26-004331): "First patient dosed in randomized study in February 2024." https://www.sec.gov/Archives/edgar/data/1498403/000117891326004331/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-26-002934): "First patient dosed in randomized study in February 2024." https://www.sec.gov/Archives/edgar/data/1498403/000117891326002934/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-003941): "First patient dosed in randomized study in February 2024." https://www.sec.gov/Archives/edgar/data/1498403/000117891325003941/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-002883): "First patient dosed in February 2024." https://www.sec.gov/Archives/edgar/data/1498403/000117891325002883/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-26-004331): "In February 2024, the first patient was dosed, with full enrollment planned in 2027." https://www.sec.gov/Archives/edgar/data/1498403/000117891326004331/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-26-002934): "In February 2024, the first patient was dosed, with full enrollment planned in 2027." https://www.sec.gov/Archives/edgar/data/1498403/000117891326002934/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-003941): "In February 2024, the first patient was dosed, with full enrollment planned in 2027." https://www.sec.gov/Archives/edgar/data/1498403/000117891325003941/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-002883): "In February 2024, the first patient was dosed, with full enrollment projected for 2027." https://www.sec.gov/Archives/edgar/data/1498403/000117891325002883/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-001952): "In February 2024, the first patient was dosed, with full enrollment projected for 2027." https://www.sec.gov/Archives/edgar/data/1498403/000117891325001952/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-001952): "First patient dosed in February 2024." https://www.sec.gov/Archives/edgar/data/1498403/000117891325001952/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-24-003823): "In February 2024, the first patient was dosed, with full enrollment projected for 2027." https://www.sec.gov/Archives/edgar/data/1498403/000117891324003823/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-24-003823): "First patient dosed in February 2024." https://www.sec.gov/Archives/edgar/data/1498403/000117891324003823/exhibit_3.htm

### 1H 2025: trial start

- Status: scheduled. Date confidence: half.
- First seen 2024-11-25, last confirmed 2024-11-25.
- Press release filed with the SEC (EX-99) (accession 0001178913-24-003823): "Anticipate initiation of pivotal clinical trial in 1H 2025" https://www.sec.gov/Archives/edgar/data/1498403/000117891324003823/exhibit_1.htm

### Feb 2025: trial start

- Status: completed. Date confidence: month.
- First seen 2025-05-27, last confirmed 2026-08-31.
- Press release filed with the SEC (EX-99) (accession 0001178913-26-004331): "First patient dosed in February 2025, with data planned in 2026*" https://www.sec.gov/Archives/edgar/data/1498403/000117891326004331/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-26-002934): "First patient dosed in February 2025, with data planned in 2026*" https://www.sec.gov/Archives/edgar/data/1498403/000117891326002934/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-003941): "First patient dosed in February 2025, with data planned in 2026*" https://www.sec.gov/Archives/edgar/data/1498403/000117891325003941/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-002883): "First patient dosed in February 2025, with data planned in 2025/2026*" https://www.sec.gov/Archives/edgar/data/1498403/000117891325002883/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-001952): "First patient dosed in February 2025, with data planned in 2025/2026*" https://www.sec.gov/Archives/edgar/data/1498403/000117891325001952/exhibit_3.htm

### Aug 2025: trial start

- Status: completed. Date confidence: month. Stage: 1/2. Indication: recurrent and progressive glioblastoma.
- First seen 2026-05-27, last confirmed 2026-08-31.
- Press release filed with the SEC (EX-99) (accession 0001178913-26-004331): "An IND application was cleared by the U.S. Food and Drug Administration (FDA) in August 2025, and in April 2026 the first patient was dosed in the first-in-human Phase 1/2 study GLIX1 for the treatment of recurrent and progressive glioblastoma (GBM) and other high-grade gliomas." https://www.sec.gov/Archives/edgar/data/1498403/000117891326004331/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-26-002934): "An IND application was cleared by the U.S. Food and Drug Administration (FDA) in August 2025, and in April 2026 the first patient was dosed in the first-in-human Phase 1/2 study GLIX1 for the treatment of recurrent and progressive glioblastoma (GBM) and other high-grade gliomas." https://www.sec.gov/Archives/edgar/data/1498403/000117891326002934/exhibit_3.htm

### Dec 2025: trial start

- Status: completed. Date confidence: month.
- First seen 2026-05-27, last confirmed 2026-08-31.
- Press release filed with the SEC (EX-99) (accession 0001178913-26-004331): "First patient dosed in December 2025" https://www.sec.gov/Archives/edgar/data/1498403/000117891326004331/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-26-002934): "First patient dosed in December 2025" https://www.sec.gov/Archives/edgar/data/1498403/000117891326002934/exhibit_3.htm

### 2026: interim data readout

- Status: scheduled. Date confidence: year.
- First seen 2024-11-25, last confirmed 2025-11-24.
- Press release filed with the SEC (EX-99) (accession 0001178913-25-003941): "Interim data planned for 2026 and full enrollment projected for 2027*" https://www.sec.gov/Archives/edgar/data/1498403/000117891325003941/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-002883): "Interim data planned for 2026 and full enrollment projected for 2027*" https://www.sec.gov/Archives/edgar/data/1498403/000117891325002883/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-001952): "Interim data expected in 2026 and full enrollment projected for 2027*" https://www.sec.gov/Archives/edgar/data/1498403/000117891325001952/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-24-003823): "Interim data expected in 2026 and full enrollment projected for 2027*" https://www.sec.gov/Archives/edgar/data/1498403/000117891324003823/exhibit_3.htm

### May 27, 2026: trial start

- Status: completed. Date confidence: exact. Stage: 1/2. Indication: Glioblastoma.
- First seen 2026-04-28, last confirmed 2026-08-31.
- Press release filed with the SEC (EX-99) (accession 0001178913-26-002934): "- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) -" https://www.sec.gov/Archives/edgar/data/1498403/000117891326002934/exhibit_1.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-26-002262): "BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)" https://www.sec.gov/Archives/edgar/data/1498403/000117891326002262/exhibit_1.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-26-002262): "TEL AVIV, Israel, and OSLO, Norway, April 28, 2026 - BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that the first patient has been dosed in the first-in-human, Phase 1/2a study of GLIX1 for the treatment of recurrent and progressive glioblastoma (GBM) and other high-grade gliomas." https://www.sec.gov/Archives/edgar/data/1498403/000117891326002262/exhibit_1.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-26-004331): "First patient dosed in April 2026; updates to the Phase 1/2a study expected in H2 2026, with full data from the Phase 1 part anticipated in 2027" https://www.sec.gov/Archives/edgar/data/1498403/000117891326004331/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-26-002934): "First patient dosed in April 2026; updates to the Phase 1/2a study expected in H2 2026, with full data from the Phase 1 part anticipated in 2027" https://www.sec.gov/Archives/edgar/data/1498403/000117891326002934/exhibit_3.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-26-002789): "19, 2026 - BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced highly encouraging new preclinical data that further support the recently initiated Phase 1/2a clinical trial evaluating" https://www.sec.gov/Archives/edgar/data/1498403/000117891326002789/exhibit_1.htm

### 1H 2027: interim data readout

- Status: scheduled. Date confidence: half. Stage: 1/2.
- First seen 2025-05-27, last confirmed 2026-04-28.
- Press release filed with the SEC (EX-99) (accession 0001178913-26-002262): "We are excited to advance GLIX1 development into this first-in-human clinical trial and look forward to initial data in the first half of 2027."" https://www.sec.gov/Archives/edgar/data/1498403/000117891326002262/exhibit_1.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-002019): "The trial is planned to be fully enrolled in 2027, and a prespecified interim analysis is planned for when 40% of PFS events are observed." https://www.sec.gov/Archives/edgar/data/1498403/000117891325002019/exhibit_1.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-001952): "Full enrollment in the randomized trial, which is being led by Columbia University, and supported by both Regeneron and BioLineRx, is planned for completion in 2027, with a prespecified interim analysis planned when 40% of progression free survival (PFS) events are observed." https://www.sec.gov/Archives/edgar/data/1498403/000117891325001952/exhibit_1.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-26-001738): ""GLIX1 has a very compelling profile supporting this Phase 1/2a study and, to that end, we look forward to initial data in the first half of 2027."" https://www.sec.gov/Archives/edgar/data/1498403/000117891326001738/exhibit_1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/motixafortide.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "APHEXDA® (motixafortide) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/motixafortide

```bibtex
@misc{secapidev_pdufa_motixafortide_20261116,
  title        = {APHEXDA® (motixafortide) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/motixafortide}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_motixafortide_20261116","title":"APHEXDA® (motixafortide) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/motixafortide","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
